Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Replimune Group, Inc. - Common Stock (NQ: REPL )

12.11 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 363
Open 12.11
Bid (Size) 11.25 (1)
Ask (Size) 14.75 (1)
Prev. Close 12.11
Today's Range 12.11 - 12.11
52wk Range 4.920 - 17.00
Shares Outstanding 46,772,263
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Replimune Group Inc
Via GlobeNewswire
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
From Replimune Group Inc
Via GlobeNewswire

Performance

YTD
-3.58%
-3.58%
1 Month
-7.70%
-7.70%
3 Month
-4.19%
-4.19%
6 Month
+16.78%
+16.78%
1 Year
+39.20%
+39.20%

More News

Read More
Tesla, ON Semiconductor And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why BP Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Replimune Group Inc
Via GlobeNewswire
Nasdaq Jumps 100 Points; Charles Schwab Profit Beats Estimates
Via Benzinga
Charles Schwab Posts Upbeat Earnings, Joins Redwire, Evolus, Replimune Group And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma
From Replimune Group Inc
Via GlobeNewswire
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Replimune Group Inc
Via GlobeNewswire
Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials
From Replimune Group Inc
Via GlobeNewswire
Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Replimune Group Inc
Via GlobeNewswire
Replimune Announces Pricing of Upsized Public Offering
From Replimune Group Inc
Via GlobeNewswire
Replimune Announces Proposed Public Offering
From Replimune Group Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Gains Over 1%; Ross Stores Earnings Top Views
Via Benzinga
Exposures Fossil Fuels
Natural Grocers By Vitamin Cottage, Elastic, Matthews International, Gap And Other Big Stocks Moving Higher On Friday
Via Benzinga
Dow Jumps 300 Points; Gap Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway
From Replimune Group Inc
Via GlobeNewswire
Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
From Replimune Group Inc
Via GlobeNewswire
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
From Replimune Group Inc
Via GlobeNewswire
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Replimune Group Inc
Via GlobeNewswire
Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
From Replimune Group Inc
Via GlobeNewswire
REPL Stock Earnings: Replimune Group Beats EPS for Q1 2025
Via InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.